In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...
A father-of-two who is in remission from cancer is calling for the treatment which helped him to be made available on the NHS ...
SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...
In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...
My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...
New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.
Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...
News Medical on MSN3d
Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatmentA groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...
more than 3,500 patients in the U.S. with this aggressive form of non-Hodgkin lymphoma experience treatment failure or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback